Novartis' Pelacarsen Fails Phase 3 Trial, Royalty Pharma Anticipates Modest Return

Novartis announced that its late‑stage HORIZON trial of pelacarsen, an experimental therapy aimed at lowering lipoprotein(a) and cardiovascular risk, failed to achieve the primary endpoint of reducing major heart events in patients with elevated Lp(a) levels . The setback marks a significant disappointment for both Novartis and its partner Ionis, as the trial was closely watched by cardiologists and investors alike.

Despite the clinical miss, Royalty Pharma, which holds pelacarsen royalties through a 2023 funding deal with Ionis that put $150 million of a $500 million total behind pelacarsen and $350 million behind Spinraza, maintains that its deal structure protects its downside. The company expects to fully recoup its investment and generate a modest positive return, citing the stability of its Spinraza royalties as a hedge against the pelacarsen outcome . Royalty also reiterated its long‑term financial goal of achieving at least $4.7 billion in portfolio receipts by 2030.

The failure underscores the challenges of targeting Lp(a), a genetically determined lipoprotein linked to residual cardiovascular risk despite optimal LDL‑cholesterol control. While the trial's negative result may dampen short‑term sentiment for Novartis and its biotech partner Ionis, the broader market will watch how the companies adjust their cardiovascular pipelines and whether alternative Lp(a) strategies can regain momentum.

Investors will likely monitor Novartis' subsequent communications for any shifts in R&D focus or reallocation of resources, as well as Royalty Pharma's upcoming earnings to see whether the anticipated modest return materializes. The outcome also serves as a reminder of the high risk inherent in late‑stage biotech collaborations, even when protective royalty agreements are in place.

Related Stocks

• NVS